Shoulder Impingement Syndrome and Graded Motor Imagery
Launched by NURAY ALACA · Oct 18, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a treatment called Graded Motor Imagery (GMI) for people suffering from Shoulder Impingement Syndrome, a common cause of shoulder pain. GMI is a holistic approach that combines treatment, education, and rehabilitation, aiming to help patients manage their pain and improve their ability to move. The study will compare the effects of GMI combined with traditional physiotherapy to traditional physiotherapy alone to see if GMI provides additional benefits in reducing pain and improving shoulder function.
To participate in this study, you must be between 20 and 50 years old and have had shoulder pain for more than six weeks, with specific symptoms indicating shoulder impingement. However, if you have had recent steroid injections, certain surgeries, or other specific health issues, you may not be eligible. Those who join the trial can expect to receive tailored treatment and assessments to measure their pain levels, shoulder movement, and other related factors. This trial is important because it aims to fill gaps in current research about effective treatments for shoulder pain, potentially leading to better care options for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 20-50 years of age with complaints of shoulder pain in the anterio-lateral region lasting more than 6 weeks, with a positive Neer impingement test and/or a positive Hawkins-Kennedy test
- • Additionally, patients must have at least one of the symptoms listed. These symptoms are: painful arch on active shoulder elevation, pain with resisted shoulder external rotation in abduction at 90°, and a positive empty can test.
- Exclusion Criteria:
- • Having had a steroid injection into the shoulder within the last 3 months
- • Previous surgery on the neck, thoracic spine or shoulder
- • Red flags (e.g. tumor, fracture, metabolic diseases, rheumatoid arthritis, osteoporosis, resting blood pressure greater than 140/90 mmHg, history of long-term steroid use)
- • History of shoulder dislocation, subluxation, fracture, adhesive capsulitis, frozen shoulder, or cervical or thoracic surgery
- • History of full-thickness rotator cuff tear
- • History of cervical disc herniation in the last 6 weeks
- • History of breast cancer on the involved side
- • Isolated acromioclavicular joint pathology (i.e., pain directly localized over the acromioclavicular joint).
- • Signs of cervical radiculopathy, radiculitis, or referred pain originating from the cervical spine
- • Receiving treatment for shoulder pain in the last 3 months
- • Being currently pregnant (Dunning, 2022)
- • Scoring ≤24 on the Standardized Mini Mental Test was determined.
About Nuray Alaca
Nuray Alaca is a dedicated clinical trial sponsor with a focus on advancing innovative therapeutic solutions through rigorous research and development. Committed to improving patient outcomes, Nuray Alaca collaborates with a network of healthcare professionals and research institutions to design and implement clinical trials that adhere to the highest ethical and scientific standards. With a strong emphasis on transparency and patient safety, the organization strives to contribute significantly to the medical community by facilitating the discovery of new treatments and enhancing the understanding of various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported